GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Gross Profit

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Gross Profit : $13.40 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Gross Profit?

Tribute Pharmaceuticals Canada's gross profit for the three months ended in Sep. 2015 was $4.26 Mil. Tribute Pharmaceuticals Canada's gross profit for the trailing twelve months (TTM) ended in Sep. 2015 was $13.40 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Tribute Pharmaceuticals Canada's gross profit for the three months ended in Sep. 2015 was $4.26 Mil. Tribute Pharmaceuticals Canada's Revenue for the three months ended in Sep. 2015 was $6.79 Mil. Therefore, Tribute Pharmaceuticals Canada's Gross Margin % for the quarter that ended in Sep. 2015 was 62.77%.

Tribute Pharmaceuticals Canada had a gross margin of 62.77% for the quarter that ended in Sep. 2015 => Durable competitive advantage


Tribute Pharmaceuticals Canada Gross Profit Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Gross Profit Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 2.37 5.22 5.64 7.92

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 3.01 2.83 3.31 4.26

Competitive Comparison of Tribute Pharmaceuticals Canada's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tribute Pharmaceuticals Canada's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Gross Profit distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's Gross Profit falls into.



Tribute Pharmaceuticals Canada Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Tribute Pharmaceuticals Canada's Gross Profit for the fiscal year that ended in Dec. 2014 is calculated as

Gross Profit (A: Dec. 2014 )=Revenue - Cost of Goods Sold
=14.631 - 6.715
=7.92

Tribute Pharmaceuticals Canada's Gross Profit for the quarter that ended in Sep. 2015 is calculated as

Gross Profit (Q: Sep. 2015 )=Revenue - Cost of Goods Sold
=6.79 - 2.528
=4.26

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.40 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Tribute Pharmaceuticals Canada's Gross Margin % for the quarter that ended in Sep. 2015 is calculated as

Gross Margin % (Q: Sep. 2015 )=Gross Profit (Q: Sep. 2015 ) / Revenue (Q: Sep. 2015 )
=(Revenue - Cost of Goods Sold) / Revenue
=4.26 / 6.79
=62.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tribute Pharmaceuticals Canada  (OTCPK:TBUFF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tribute Pharmaceuticals Canada had a gross margin of 62.77% for the quarter that ended in Sep. 2015 => Durable competitive advantage


Tribute Pharmaceuticals Canada Gross Profit Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines